Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Abstract

Compositions and methods for treating MM are provided herein.

1 - 63 . (canceled) 
     
     
         64 . A method of treating multiple myeloma in a subject, comprising administering to a subject in need thereof a first pharmaceutical composition comprising a therapeutically effective amount of an anti-CS1 antibody and a second pharmaceutical composition comprising a therapeutically effective amount of lenalidomide. 
     
     
         65 . The method of  claim 64 , wherein the anti-CS1 antibody binds the epitope covered by amino acids 170 to 227 of SEQ ID NO:1. 
     
     
         66 . The method of  claim 65 , wherein the anti-CS1 antibody further binds the epitope covered by amino acids 23 to 151 of SEQ ID NO:1 or the epitope covered by amino acids 68 to 151 of SEQ ID NO:1. 
     
     
         67 . The method of  claim 64 , wherein the anti-CS1 antibody is HuLuc63, said HuLuc63 being a humanized IgG 1  antibody comprising the heavy chain variable region of SEQ ID NO:5 and the light chain variable region of SEQ ID NO:6. 
     
     
         68 . The method of  claim 64 , in which the anti-CS1 antibody is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg. 
     
     
         69 . The method of  claim 67 , in which the HuLuc63 is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg. 
     
     
         70 . The method of  claim 68 , in which lenalidomide is administered orally at a dosage from approximately 1 mg/day to 50 mg/day. 
     
     
         71 . A method of treating multiple myeloma in a subject, comprising administering to a subject in need thereof a first pharmaceutical composition comprising a therapeutically effective amount of an anti-CS1 antibody, a second pharmaceutical composition comprising a therapeutically effective amount of lenalidomide, and a therapeutically effective amount of dexamethasone. 
     
     
         72 . The method of  claim 71 , wherein the anti-CS1 antibody binds the epitope covered by amino acids 170 to 227 of SEQ ID NO:1. 
     
     
         73 . The method of  claim 72 , wherein the anti-CS1 antibody further binds the epitope covered by amino acids 23 to 151 of SEQ ID NO:1 or the epitope covered by amino acids 68 to 151 of SEQ ID NO:1. 
     
     
         74 . The method of  claim 71 , wherein the anti-CS1 antibody is HuLuc63, said HuLuc63 comprising a humanized IgG 1  antibody comprising the heavy chain variable region of SEQ ID NO:5 and the light chain variable region of SEQ ID NO:6. 
     
     
         75 . The method of  claim 71 , in which the anti-CS1 antibody is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg. 
     
     
         76 . The method of  claim 74 , in which the HuLuc63 is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg. 
     
     
         77 . The method of  claim 75 , in which lenalidomide is administered orally at a dosage from approximately 1 mg/day to 50 mg/day. 
     
     
         78 . A method of treating multiple myeloma in a subject, comprising administering to a subject in need thereof a first pharmaceutical composition comprising a therapeutically effective amount of an anti-CS1 antibody, a second pharmaceutical composition comprising a therapeutically effective amount of lenalidomide, and a third pharmaceutical composition comprising a therapeutically effective amount of bortezomib. 
     
     
         79 . The method of  claim 78 , wherein the anti-CS1 antibody binds the epitope covered by amino acids 170 to 227 of SEQ ID NO:1. 
     
     
         80 . The method of  claim 79 , wherein the anti-CS1 antibody further binds the epitope covered by amino acids 23 to 151 of SEQ ID NO:1 or the epitope covered by amino acids 68 to 151 of SEQ ID NO:1. 
     
     
         81 . The method of  claim 78 , wherein the anti-CS1 antibody is HuLuc63, said HuLuc63 being a humanized IgG 1  antibody comprising the heavy chain variable region of SEQ ID NO:5 and the light chain variable region of SEQ ID NO:6. 
     
     
         82 . The method of  claim 78 , in which the anti-CS1 antibody is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg. 
     
     
         83 . The method of  claim 81 , in which the HuLuc63 is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg. 
     
     
         84 . The method of  claim 82 , in which lenalidomide is administered orally at a dosage from approximately 1 mg/day to 50 mg/day. 
     
     
         85 . A method of treating multiple myeloma in a subject, comprising administering to a subject in need thereof a first pharmaceutical composition comprising a therapeutically effective amount of an anti-CS1 antibody, a second pharmaceutical composition comprising a therapeutically effective amount of lenalidomide, a third pharmaceutical composition comprising a therapeutically effective amount of bortezomib, and a therapeutically effective amount of dexamethasone. 
     
     
         86 . The method of  claim 85 , wherein the anti-CS1 antibody binds the epitope covered by amino acids 170 to 227 of SEQ ID NO:1. 
     
     
         87 . The method of  claim 86 , wherein the anti-CS1 antibody further binds the epitope covered by amino acids 23 to 151 of SEQ ID NO:1 or the epitope covered by amino acids 68 to 151 of SEQ ID NO:1. 
     
     
         88 . The method of  claim 85 , wherein the anti-CS1 antibody is HuLuc63, said HuLuc63 being a humanized IgG 1  antibody comprising the heavy chain variable region of SEQ ID NO:5 and the light chain variable region of SEQ ID NO:6. 
     
     
         89 . A method of treating multiple myeloma in a subject, comprising administering to a subject in need thereof a first pharmaceutical composition comprising a therapeutically effective amount of an anti-CS1 antibody, a second pharmaceutical composition comprising a therapeutically effective amount of bortezomib, and a therapeutically effective amount of dexamethasone. 
     
     
         90 . The method of  claim 89 , wherein the anti-CS1 antibody binds the epitope covered by amino acids 170 to 227 of SEQ ID NO:1. 
     
     
         91 . The method of  claim 90 , wherein the anti-CS1 antibody further binds the epitope covered by amino acids 23 to 151 of SEQ ID NO:1 or the epitope covered by amino acids 68 to 151 of SEQ ID NO:1. 
     
     
         92 . The method of  claim 89 , wherein the anti-CS1 antibody is HuLuc63, said HuLuc63 being a humanized IgG 1  antibody comprising the heavy chain variable region of SEQ ID NO:5 and the light chain variable region of SEQ ID NO:6.